Key result
Implantable cardioverter-defibrillator therapy selection based solely on LVEF ≤35% is insufficient for predicting sudden death risk in non-ischaemic dilated cardiomyopathy.
Current guidelines relying solely on LVEF ≤35% for primary prevention ICDs in non-ischaemic DCM are inadequate, and a multiparametric approach incorporating imaging and genetics is needed.
No takes yet. Share an insight, caveat, or question.
LVEF ≤35% alone warrants caution for primary prevention ICD decisions in non-ischaemic DCM; leaves open validation of multiparametric risk models.
Disertori et al. (2013) conducted a review in Non-ischaemic dilated cardiomyopathy (DCM). Implantable cardioverter-defibrillator (ICD) therapy was evaluated on Sudden death. Implantable cardioverter-defibrillator therapy selection based solely on LVEF ≤35% is insufficient for predicting sudden death risk in non-ischaemic dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: